Medigen Vaccine Biologics Asset Resilience Ratio

Latest as of June 2026: 37.48%

Medigen Vaccine Biologics asset resilience ratio. Medigen Vaccine Biologics (6547) has an Asset Resilience Ratio of 37.48% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 6547 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Liquid Assets

NT$1.78 Billion
≈ $56.22 Million USD Cash + Short-term Investments

Total Assets

NT$4.76 Billion
≈ $149.99 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of Medigen Vaccine Biologics (2014–2025)

Asset resilience ratio of Medigen Vaccine Biologics from 2014 to 2025. This chart shows how Medigen Vaccine Biologics's Asset Resilience Ratio has changed over time. Read how much debt does Medigen Vaccine Biologics carry for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Medigen Vaccine Biologics's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 6547 current and non-current assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents NT$0.00 0%
Short-term Investments NT$1.78 Billion 37.48%
Total Liquid Assets NT$1.78 Billion 37.48%

Asset Resilience Insights

  • Very High Liquidity: Medigen Vaccine Biologics maintains exceptional liquid asset reserves at 37.48% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Medigen Vaccine Biologics Industry Peers by Asset Resilience Ratio

Compare Medigen Vaccine Biologics's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
argenx NV ADR
NASDAQ:ARGX
Biotechnology 15.95%
Argen-X
F:1AE
Biotechnology 10.93%
Ascendis Pharma AS
F:A71
Biotechnology 0.00%
Halozyme Therapeutics Inc
NASDAQ:HALO
Biotechnology 1.28%
Abivax SA American Depositary Shares
NASDAQ:ABVX
Biotechnology 4.91%
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
Biotechnology 16.06%
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392
Biotechnology 10.35%
SOLENO THERAPEUT. DL-001
F:6XC
Biotechnology 41.74%

Medigen Vaccine Biologics Asset Resilience Ratio by Year (2014–2025)

Medigen Vaccine Biologics asset resilience ratio by year from 2014 to 2025. The table below shows the annual Asset Resilience Ratio data for Medigen Vaccine Biologics.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 30.11% NT$1.18 Billion
≈ $37.32 Million
NT$3.93 Billion
≈ $123.94 Million
+2.61pp
2024-12-31 27.50% NT$1.20 Billion
≈ $37.81 Million
NT$4.36 Billion
≈ $137.49 Million
-11.96pp
2023-12-31 39.46% NT$2.40 Billion
≈ $75.75 Million
NT$6.09 Billion
≈ $191.95 Million
-1.81pp
2022-12-31 41.28% NT$3.03 Billion
≈ $95.55 Million
NT$7.35 Billion
≈ $231.49 Million
+25.18pp
2021-12-31 16.10% NT$853.10 Million
≈ $26.88 Million
NT$5.30 Billion
≈ $166.95 Million
+14.58pp
2020-12-31 1.52% NT$53.17 Million
≈ $1.68 Million
NT$3.49 Billion
≈ $109.98 Million
-0.81pp
2019-12-31 2.34% NT$53.23 Million
≈ $1.68 Million
NT$2.28 Billion
≈ $71.74 Million
-20.68pp
2018-12-31 23.02% NT$502.52 Million
≈ $15.83 Million
NT$2.18 Billion
≈ $68.78 Million
+22.88pp
2017-12-31 0.14% NT$2.97 Million
≈ $93.57K
NT$2.14 Billion
≈ $67.31 Million
-1.15pp
2016-12-31 1.29% NT$23.46 Million
≈ $739.02K
NT$1.82 Billion
≈ $57.26 Million
+0.06pp
2015-12-31 1.23% NT$20.32 Million
≈ $640.19K
NT$1.65 Billion
≈ $52.09 Million
-32.62pp
2014-12-31 33.85% NT$411.20 Million
≈ $12.96 Million
NT$1.21 Billion
≈ $38.27 Million
--
pp = percentage points

About Medigen Vaccine Biologics

TWO:6547 Taiwan Biotechnology
Market Cap
$407.56 Million
NT$12.94 Billion TWD
Market Cap Rank
#12600 Global
#435 in Taiwan
Share Price
NT$39.35
Change (1 day)
-7.08%
52-Week Range
NT$35.50 - NT$68.10
All Time High
NT$280.20
About

Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for th… Read more